RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma Meeting Abstract


Authors: Fuchs, C. S.; Shitara, K.; Di Bartolomeo, M.; Lonardi, S.; Al-Batran, S. E.; Van Cutsem, E.; Ilson, D. H.; Tabernero, J.; Chau, I.; Ducreux, M.; Mendez, G. A.; Alavez, A. M.; Takahari, D.; Mansoor, W.; Lacy, J.; Gorbunova, V.; Ferry, D.; Lin, J.; Das, M.; Shah, M. A.
Abstract Title: RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma
Meeting Title: 2018 Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 4 Suppl.
Meeting Dates: 2018 Jan 18-20
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-01
Language: English
ACCESSION: WOS:000436174100006
PROVIDER: wos
DOI: 10.1200/JCO.2018.36.4_suppl.5
Notes: Meeting Abstract: 5 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David H Ilson
    433 Ilson